Coronavirus / COVID

FDA clearance paves the way for Invivyd to launch 2 phase 3 trials of VYD2311, a monoclonal antibody designed as a safe, convenient, vaccine alternative for COVID-19 prevention.

Georges C.Benjamin, MD, executive director of the American Public Health Association, details practical implications for clinical teams.

In part 1 of our conversation, the VP of the NFID discusses ACIP’s recent meeting, including COVID-19 shared decision-making, informed-consent debates, and new policy actions on hepatitis B and MMRV.

Insights from Jaya Aysola, MD, MPH, DTMH; and John C. Lin, MD candidate, on clinical workflows, social needs screening, and policy levers.

Oxford’s Prof Katrina Lythgoe and Mahan Ghafari, DPhil, report ONS-CIS data on 576 persistent UK infections with rapid within-host evolution and rare transmission after one month.

William Hanage, PhD, discusses viral evolution, transmission risk, and clinical implications for immunocompromised patients.

Single-center randomized trial shows lower infection rates and extended time to SARS-CoV-2 infection, though larger studies are needed to confirm findings.

Supported by phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.

Robert Hopkins, Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses what patients are asking about with regards to the vaccines and what the general public should continue to know about their medical value.

Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.

New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.

Allergist and immunologist Juanita Mora, MD, urges vaccination, masking, and outreach to safeguard vulnerable communities.

New data show consistent late-summer and winter surges, reinforcing the need for seasonal vaccine timing and focused protection for high-risk groups.

STOP-PASC substudy results find digital biometrics align with symptom burden, supporting their use as objective measures in long COVID research.

First-in-class IL-15 agonist aims to address persistent post-COVID symptoms by enhancing immune clearance and restoring T cell memory.

Julia Moore Vogel, PhD, says the LoCITT study aims to expand access through a fully remote design using CareEvolution’s MyDataHelps platform.

Ep 2, Part 2 of 4, Robert Bransfield, MD, discusses how microbes may influence violent behavior and global instability through biological and environmental pathways.

Pathologist Leilani Valdes, MD, MBA, FCAP, explains the role of PCR testing, early surveillance, and vaccine education in protecting community health.

Sharon Nachman, MD, breaks down the latest on Stratus and Nimbus variants and what families should consider as schools resume.

Cost-effectiveness of COVID-19 vaccination in older adults amid rising US cases and limited booster access.

Low vaccine uptake, immunity gaps, and new antiviral data raise alarms ahead of a potential late-summer surge.

Study investigators found a therapy designed to treat Celiac disease supported a more rapid return to normal activities for patients with multisystem inflammatory syndrome in children (MIS-C).

Vinay Prasad’s, MD, MPH, short tenure marked by tough regulatory decisions and political pushback; the Trump administration has not yet named a successor for the CBER director role.

Ep 2, Part 1 of 4: How infectious diseases may fuel global instability in a conversation with psychiatrist Robert Bransfield, MD.

New research reveals accelerated brain aging in healthy adults during the COVID-19 pandemic, highlighting broader neurological and social effects.